clinical trial · NCT05664737
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
Bristol-Myers Squibb·phase2·recruiting·n = 189
AnemiaLuspaterceptPlacebo
brief summary
The purpose of the study is to evaluate the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in adult participants with α-thalassemia hemoglobin H (HbH) disease and determine the safety and drug levels in adolescent participants.
started
Dec 9, 2022
primary completion
Jul 16, 2027
completion
Aug 14, 2034
last updated
Mar 24, 2026
official title
A Phase 2, Study for the Treatment of Anemia With Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol